DB Life Insurance secured a three-month exclusive selling right for an AI-powered cancer insurance product on July 6, 2026, entering a market where larger rivals already offer similar plans and where new financial AI oversight rules took effect just weeks earlier. The (Non-participating) AI Life Care Cancer Insurance links individual health grades to premium discounts and includes an AI Health Coaching Service, according to The Asia Business Daily.
Oh Hyunjung, head of the New Growth task force at DB Life, said: "This product is designed so that AI precisely assists customers in health management and ensures that their efforts to maintain good health translate into tangible benefits such as reduced insurance premiums."
How the exclusivity system works
The Korea Life Insurance Association's new-product review committee granted the three-month exclusivity after judging the product to show originality and usefulness. During the grant period, competing insurers cannot sell an equivalent product. Financial authorities widened the possible grant length from three-to-12 months to six-to-18 months in the second half of 2025, Seoul Economic Daily reported. DB Life's three-month term sits at the lower end of that scale.
Applications for exclusivity rights have risen sharply. Domestic insurers filed 31 applications in the third quarter of 2025, a 138% increase from a year earlier, surpassing full-year totals for 2024 and 2023, according to the General Insurance Association of Korea. Recent grants have covered dementia-assessment coverage, pet insurance, and a policy reimbursing transport costs during subway delays.
Short grants carry commercial limits. Seoul Economic Daily reported that one insurer holding six-month exclusivity sold only dozens of policies, citing an industry view that agents avoid products with complex structures. "When products are too complex, agents avoid selling them - that's the dilemma," an industry official said.
Larger rivals moved first
Hanwha Life introduced an AI-powered cancer insurance plan in September 2025 in partnership with health care start-up Need. "The new insurance plan goes beyond providing simple coverage upon cancer diagnosis, offering customized protection to customers through Need's AI-powered Cancer Protection System," a Hanwha Life official said.
Samsung Life, Kyobo Life, and Hanwha Life, South Korea's three largest life insurers by premium, have all been expanding their use of AI, including in underwriting, claims processing and customer-facing services. AI for Insurance Courses help professionals keep pace with these shifts, offering training on practical AI applications in the industry. Hanwha Life separately used AI document processing to structure roughly five million historical claims for cancer-product design, according to a case study published by vendor Upstage. The broader South Korean life and non-life market is projected to grow from US$190.0 billion in 2025 to $197.47 billion in 2026, Mordor Intelligence reported, with insurers pivoting toward protection-type products amid an aging population.
Regulators tighten AI oversight
The Financial Services Commission's AI guidelines for the financial sector took effect June 22, 2026, applying to all financial companies across seven areas including governance, human supervision, and data and model credibility. Under the human-supervision principle, AI is treated as an assistive tool, with final decision-making authority resting with a human supervisor. The framework is currently self-regulatory, but the FSC has signalled it is an interim step.
The guidelines follow the AI Basic Act, which took effect Jan. 22, 2026, setting governance and compliance standards for AI while promoting innovation. Products that tie verified health data to pricing sit at the intersection of these frameworks and Korea's personal-data rules. RNA Analytics noted that the long-term consequences of AI decisions using sensitive health data bring rules comparable to Article 22 of the European Union's General Data Protection Regulation into play, requiring clear explainability and consent protocols.
A structural question for risk pooling
Products that price on individual health data raise a tension between efficient risk identification and the pooling function on which insurance rests. Research published in The Geneva Risk and Insurance Review found that when data-driven classification is inexpensive, insurers have an incentive to adopt maximal granularity, treating each subpopulation as a separate risk class. Behaviour-linked pricing that converts individual health grades into premium discounts sits directly on that tension.
Global survey data indicates the industry remains cautious about deeper AI deployment. A GlobalData poll conducted across the first and second quarters of 2026, covering 113 respondents, found close to one-quarter viewed AI as not ready for broad use in insurance. "Regulation has not fully caught up yet and there is concern around who is liable for mistakes made by AI," said Ben Carey-Evans, senior insurance analyst at GlobalData.
Why this matters for insurance professionals
DB Life's three-month exclusivity will lapse in October 2026, after which competitors may offer comparable products. The push toward AI-driven, behaviour-linked pricing in health insurance, combined with new regulatory frameworks, means professionals in underwriting, product design, and compliance must understand how AI models use sensitive health data and how human oversight requirements affect decision-making. The trend toward exclusivity grants also signals that insurers are racing to differentiate through AI, making familiarity with these tools a competitive necessity.
Your membership also unlocks:
